News

May 28, 2020May 28, 2020

3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

News

For breast cancer care during the COVID-19 pandemic, a panel of experts has recommended that patients be divided into one of three categories based on the severity of their ... Read more

May 21, 2020May 21, 2020

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

News

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new ... Read more

May 14, 2020May 14, 2020

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

News

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Seattle Genetics‘ Tukysa, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with metastatic HER2-positive breast cancer. Tukysa is now approved ... Read more

May 7, 2020May 14, 2020

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

News

Seattle Genetics’ Tukysa (tucatinib) can now be used in combination with trastuzumab and Xeloda (capecitabine) to treat people with metastatic or inoperable HER2-positive breast cancer following its approval by ... Read more

April 30, 2020April 30, 2020

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

News

Enhertu (trastuzumab deruxtecan) has been approved in Japan to treat adults with HER2-positive inoperable or metastatic breast cancer that is resistant to chemotherapy, or those who cannot tolerate it. Enhertu is ... Read more

April 28, 2020April 28, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in ... Read more

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic ... Read more

April 16, 2020April 16, 2020

Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment

News

Concure Oncology plans to use $2.5 million in new funding to help make its targeted radiation treatment option increasingly available to early-stage breast cancer patients. Specifically, the funding round is ... Read more

April 9, 2020April 9, 2020

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

News

Immunomedics has halted its Phase 3 confirmatory trial of sacituzumab govitecan, due to strong evidence of its ability to delay disease progression in patients with advanced triple-negative breast cancer ... Read more

April 2, 2020April 2, 2020

CytoDyn Seeks Preliminary FDA Meeting on Leronlimab’s Breakthrough Therapy Status

News

After a recommendation from the U.S. Food and Drug Administration (FDA), CytoDyn is planning to ask the regulatory agency for a preliminary meeting to discuss the granting of breakthrough therapy ... Read more

Pin It on Pinterest